

Display Settings:  Abstract[Neurology. 2001 Jan 9;56\(1\):118-20.](#)

## PCV chemotherapy for recurrent glioblastoma multiforme.

[Kappelle AC](#), [Postma TJ](#), [Taphoorn MJ](#), [Groeneveld GJ](#), [van den Bent MJ](#), [van Groenigen CJ](#), [Zonnenberg BA](#), [Sneeuw KC](#), [Heimans JJ](#).

Departments of Neurology and Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.

### Abstract

The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status > or = 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.

### Comment in

[Neurology. 2001 Jun 26;56\(12\):1782.](#)

PMID: **11148250** [PubMed - indexed for MEDLINE]

[+](#) **Publication Types, MeSH Terms, Substances, Supplementary Concepts**

[+](#) **LinkOut - more resources**